Olutasidenib with Co-targeted Therapy for IDH1-Mutated Myeloid Malignancies
This study is looking at different combinations of medicines for people with certain types of blood cancers (relapsed/refractory AML, high-risk MDS, MPN, or MDS/MPN) that have an IDH1 mutation. Researchers want to see how safe and tolerable these combinations are. The main medicine being studied is olutasidenib, which will be given with other drugs like cladribine, venetoclax, gilteritinib, or ruxolitinib. To join, you must be at least 18 years old and have a documented IDH1 mutation in your cancer. The study aims to see how many people have a complete remission (when signs of cancer disappear) with these treatments. The study is currently unclear on its recruitment status and plans to enroll 68 participants.
- Study design
- This interventional study plans to enroll 68 participants. It is testing olutasidenib in combination with other drugs in three different groups.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Safety and side effects will be measured throughout the study, for an average of 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Courtney DiNardo, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Safety and adverse events (AEs)Through study completion; an average of 1 year
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0